Bayer Aktiengesellschaft

Bayer Schering Pharma Ag

Forward Pharma A/s

Fwp IP Aps

Roland Rupp

Manfred Bucheler

Venkata-Rangarao Kanikanti

Takaaki Nishioka

Andreas Ohm

Helmut Luchtenberg

Erhard Schellmann

Jan-Olav Henck

Peter Deuringer

Yoshifumi Katakawa

Chika Taniguchi

Hitoshi Ichihashi

Wolfgang Weber

Martin Ullrich

Miklos Von Bittera

Josef Schmoll

Viktor Trescher

Norbert Pollinger

Johannes Michaelis

Heino Stab

Ernst Bocker

Wolfgang Kracht

Klaus Benke

Rolf Dhein

Rolf-Volker Meyer

Ulrich Von Gizycki

Reinhold Hornle

Dietmar Schapel

Kurt Bauer

Hans-Heinz Molls

Robert Kuth

Hildegard Schnoring

Georg Wiessmeier

Erhard Herrmann

Ahmed Hegasy

Claus Weisemann

Axel Wollenschlager

Klaus-Dieter Ramsch

Bernd Krumbach

Lothar Weismantel

Erich Brendel

Ernst Chantraine

Bernd K&uuml;hn

Eduard Porges

Henrik Nilsson

Heinrich Feltkamp

J&uuml;rgen Klein

Volker Pilz

Heino Staβ

Peder M Andersen

Theis Terwey

A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix

The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.

Sustained-release preparations of quinolone antibiotics

Method of preparing sustained-release preparations of quinolone antibiotics

Sustained-release preparations of quinolone antibiotics and method for preparation thereof

The present invention relates to orally administrable multiple-unit sustained-release dose forms having controlled agitation-independent release of active compound and processes for their production using a selected erodable hydrophilic polymer (HPC) and a limitation of the maximum size of the active compound-containing polymer particles to &lE;3 mm.

Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same

Method for the in situ formulation of a medicinal substance solution for parenteral administration, in which at least two metered part-streams are continuously combined with the aid of a mixer to an active ingredient-containing total volumetric flow, characterized in that the resulting medicinal substance solution is not in thermodynamic equilibrium, and in that the resulting total volumetric flow after mixing is 0.2 ml/h to 500 ml/h, preferably 5 ml/h to 500 ml/h, an apparatus for carrying out the method, and an active ingredient administration kit which contains the apparatus.

Method and device for in-situ formulation of a medicinal solution for parenteral application

The invention relates to flavor-masked pharmaceutical compositions for oral administration, their preparation and their use as medicaments. The new pharmaceutical preparations according to the invention make it possible to administer pharmaceutical active substances having very unpleasant organoleptic properties such as, for example, very bad taste, even in liquid form.

Flavor-masked pharmaceutical compositions

The invention relates to flavour-masked pharmaceutical compositions for oral administration, their preparation and their use as medicaments. The new pharmaceutical preparations according to the invention make it possible to administer pharmaceutical active substances having very unpleasant organoleptic properties such as, for example, very bad taste, even in liquid form.

Controlled release medicament pellets comprising

Medicaments having controlled release of the active compound

A solid medicament preparation having long-lasting action containing a sparingly soluble dihydropyridine active compound of the Formula (I) ##STR1## the preparation having a core-coating construction, the core containing at least one of the above mentioned dihydropyridines in slow-release form, the inner-most coating situated around the core contains no active compound and only dissolves slowly and adjacent to the inner-most coating a rapid release initial dose of the active compound mixed with a polymer.

DHP delayed release preparation

A pharmaceutical formulation tablet with a long-lasting action for 1 to 2 daily doses having a diameter between about 0.5 and 15 mm and comprising

Dihydropyridine depot formulation

The present disclosure is concerned with self-adhesive sheet-like structures made by adhering an adhesive polyurethane gel material to a supporting substrate and the utilization of such structures in the medical field to adhere materials such as plasters, wound dressings and appliances to the human body, and in other fields to connect articles, such as the parts of a fractured or cracked object, to one another by means of an adhesive bond. The gel is formed by immobilizing a high molecular weight polymeric polyol in the matrix of a covalently crosslinked polyurethane which is prepared by reacting polyisocyanates having an isocyanate functionality of at least 2 with higher molecular weight polyhydroxyl compounds having a hydroxyl functionality of at least 3. These reactants are selected in accordance with the following formula which relates the isocyanate number, K, (isocyanate to hydroxyl equivalents ratio times 100) to the average functionalities of the polyisocyanates (F.sub.I) and of the polyhydroxyl compounds (F.sub.P) as follows: ##EQU1## wherein X is less than or equal to 120. These reactants are also selected to give a weight ratio of matrix to immobilized polymeric polyol of between about 15:85 and 62:38.

Self-adhesive sheet-like structures, process for their preparation and

In a therapeutic system such as a plaster for administration of an active compound through the skin and comprising a covering layer which is essentially impermeable to the active compound an active compound reservoir layer and a protective layer which can be pulled off and which is essentially impermeable to the active compound, the improvement wherein the reservoir layer contains about 1-30% of active compound in an elastomer mixture comprising at least one of polyisobutylene, polybutadiene oil and paraffin oil, and a tackifying resin. Thereby the active compound can be released in regulated relatively large quantity over a prolonged period of time.

Isobutylene polymer active compound release systems

In the treatment of cardiovascular and coronary disorders by administering to a patent suffering therefrom a solid preparation comprising nifedipine, the improvement which comprises administering such nifedipine in the form of a solid two-phase medicament formulation comprising a nifedipine coprecipitate, in which the nifedipine is present in a non-crystalline form, and crystalline nifedipine, whereby the nifedipine rapidly enters the blood stream in a relatively high concentration which is maintained for a relatively long time.

Two-phase formulation

The present invention relates to a process for freeing solids, in particular pharmaceutical active ingredients, from germs by sterile filtration using supercritical gases.

Process for rendering solids sterile

Growing community of inventors

Bergisch Gladbach, Germany

Roland Rupp